Key Highlights
- DA Davidson slashed UiPath’s rating to Underperform from Neutral, slicing the price target down to $10.
- Analyst concerns stem from customer resistance to AI pricing models discussed at the company’s FUSION event and Investor Day.
- PATH shares have declined 8% in the past week, trading beneath both 50-day and 200-day moving averages.
- The consensus Wall Street rating sits at Hold, with analysts projecting an average target price of $15.69.
- Despite topping Q2 revenue and earnings forecasts, company insiders unloaded more than $24 million worth of shares in three months.
Shares of UiPath (PATH) face renewed selling pressure following a bearish call from DA Davidson, which downgraded the automation software company to Underperform from Neutral. The firm simultaneously slashed its price objective to $10, representing significant downside from current trading levels.
The stock commenced trading at $12.23 and has surrendered 8% of its value throughout the last week. This decline positions PATH beneath its 50-day moving average of $14.53 and dangerously close to its 200-day moving average of $12.24.
DA Davidson analyst Lucky Schreiner identified pricing headwinds as the primary catalyst for the negative outlook adjustment. These concerns emerged after the firm participated in UiPath’s FUSION conference and subsequent Investor Day presentations.
During these gatherings, UiPath unveiled a vertical-focused go-to-market approach alongside pre-configured solutions designed to accelerate time-to-value for clients. Management emphasized its commitment to deterministic outcomes and enterprise-scale implementations when clients integrate orchestration capabilities with automation frameworks.
However, responses from customers and channel partners attending the event proved inconsistent. According to DA Davidson, significant resistance to the company’s AI pricing structure emerged as the most notable concern.
Analyst Community Remains Divided on PATH
DA Davidson’s pessimistic stance doesn’t reflect universal sentiment across Wall Street. The aggregate analyst rating on PATH continues to register as Hold, with the mean price objective landing at $15.69.
Multiple investment firms have adjusted their targets downward recently while maintaining neutral positions. BMO Capital Markets reduced its forecast to $15 from $18, and UBS trimmed its target to $15 from $19 following UiPath’s decision not to provide preliminary fiscal 2028 revenue guidance.
TD Cowen maintained a $16 objective with a Hold recommendation, whereas RBC Capital lowered its target to $15 citing execution risks. Truist Securities brought its forecast down to $14, and Bank of America increased its target to $15 while retaining an Underperform stance.
In total, four analysts assign PATH a Buy rating, fifteen recommend Hold, and two advocate Sell.
Financial Performance and Insider Transactions
UiPath’s most recent quarterly results, disclosed on September 3, exceeded Wall Street expectations. The company delivered earnings per share of $0.15, meeting projections, while revenue reached $410.26 million compared to the $397.77 million consensus estimate.
Top-line growth registered at 13.3% on a year-over-year basis. The company posted a net margin of 21.03% and generated a return on equity of 9.70%. Analysts currently project full-year earnings per share of $0.49.
Insider selling activity has intensified as the stock price weakened. Raghavendra Malpani offloaded 40,464 shares on September 17 at an average of $14.00 per share, generating proceeds of $566,496.
Chief Operating Officer Ashim Gupta disposed of 117,339 shares on September 11 at a mean price of $13.85, totaling approximately $1.63 million. This transaction reduced his stake by 5.45%.
Throughout the previous 90-day period, corporate insiders have collectively sold 1.56 million PATH shares valued at $24.7 million. Insiders maintain ownership of 22.44% of the company.
Institutional investors command a more substantial portion of UiPath, controlling 62.5% of shares outstanding. Multiple funds have expanded their holdings in recent quarters, including Allworth Financial LP and Corient Private Wealth LLC.
UiPath currently trades with a market capitalization of $6.37 billion, a price-to-earnings ratio of 18.25, and a beta coefficient of 1.02. The stock’s 52-week trading range extends from $9.20 to $19.84.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
